JP2024527109A5 - - Google Patents

Info

Publication number
JP2024527109A5
JP2024527109A5 JP2024505416A JP2024505416A JP2024527109A5 JP 2024527109 A5 JP2024527109 A5 JP 2024527109A5 JP 2024505416 A JP2024505416 A JP 2024505416A JP 2024505416 A JP2024505416 A JP 2024505416A JP 2024527109 A5 JP2024527109 A5 JP 2024527109A5
Authority
JP
Japan
Prior art keywords
kras
poziotinib
inhibitor
pharmaceutical product
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505416A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527109A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/074317 external-priority patent/WO2023010121A1/en
Publication of JP2024527109A publication Critical patent/JP2024527109A/ja
Publication of JP2024527109A5 publication Critical patent/JP2024527109A5/ja
Pending legal-status Critical Current

Links

JP2024505416A 2021-07-29 2022-07-29 Kras変異体がんの処置のための方法および組成物 Pending JP2024527109A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227237P 2021-07-29 2021-07-29
US63/227,237 2021-07-29
PCT/US2022/074317 WO2023010121A1 (en) 2021-07-29 2022-07-29 Methods and compositions for treatment of kras mutant cancer

Publications (2)

Publication Number Publication Date
JP2024527109A JP2024527109A (ja) 2024-07-19
JP2024527109A5 true JP2024527109A5 (cg-RX-API-DMAC7.html) 2025-08-05

Family

ID=85087345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505416A Pending JP2024527109A (ja) 2021-07-29 2022-07-29 Kras変異体がんの処置のための方法および組成物

Country Status (7)

Country Link
US (1) US20240374597A1 (cg-RX-API-DMAC7.html)
EP (1) EP4376959A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527109A (cg-RX-API-DMAC7.html)
KR (1) KR20240051145A (cg-RX-API-DMAC7.html)
CN (1) CN118043075A (cg-RX-API-DMAC7.html)
CA (1) CA3227802A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023010121A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
CN121846289A (zh) * 2024-10-12 2026-04-14 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 包括nampt抑制剂和kras抑制剂的组合物及其用途
CN119607214B (zh) * 2025-02-17 2025-06-20 四川大学华西医院 Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112043A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
WO2021148581A1 (en) * 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021298154A1 (en) * 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
KR102379786B1 (ko) * 2020-08-13 2022-03-25 정부환 레일 형식 보행보조기구 방향전환장치

Similar Documents

Publication Publication Date Title
US20250295869A1 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
Manic et al. Chloroquine and hydroxychloroquine for cancer therapy
De Oliveira et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis
NO20066056L (no) Behandling med Gemcitabin og en EGFR-inhibitor
JP2019532051A5 (cg-RX-API-DMAC7.html)
AU2015326196B2 (en) Pharmaceutical composition for treating ulcerative colitis
JP2020500152A5 (cg-RX-API-DMAC7.html)
JP2023533464A5 (cg-RX-API-DMAC7.html)
JP2019510785A5 (cg-RX-API-DMAC7.html)
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
IL320562A (en) Cancer treatment methods
NO20066054L (no) behandling med cisplatin og en EGFR-inhibitor
WO2021063332A1 (zh) 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途
JP2024502446A5 (cg-RX-API-DMAC7.html)
Kogure et al. Cytokine release syndrome with pseudoprogression in a patient with advanced non–small cell lung cancer treated with pembrolizumab
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
KR20190018632A (ko) Phy906 추출물, 황금(s) 추출물 또는 이러한 추출물로부터의 화합물을 포함하는 병용 요법을 이용한 항-면역 체크포인트 억제제의 개선된 치료 지수
EP4489756A1 (en) Methods of treating small cell lung cancer
NO20066080L (no) Behandling med irinotecan (CPT-11) og en AGFR-inhibitor
WO2023272831A1 (zh) 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用
JP2025521501A5 (cg-RX-API-DMAC7.html)
JPWO2022260132A5 (cg-RX-API-DMAC7.html)
RU2020126340A (ru) Способы и комбинированное терапевтическое средство для лечения рака
JP2022504760A5 (cg-RX-API-DMAC7.html)